Buprenorphine in Acute Renal Colic Pain Management
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 1417613151
- TUMS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical diagnosis of acute renal colic; positive urinalysis of hematuria; pain score more than 3 in Numerical Rating Score (NRS); patients sign the informed consent to enroll.
Exclusion Criteria:
- previous history of seizures; cardiovascular, hepatic, renal or metabolic diseases;
- febrile patients (T > 38°C);
- hemodynamically unstable patients ( Systolic Blood Pressure < 90 mmHg);
- pregnant patients;
- patients with abdominal tenderness as a sign of peritoneal inflammation;
- any clinical suspicion for diseases other than urolithiasis like abdominal aortic aneurysm or dissection;
- patients with a history of drug addiction or known allergy to opioids;
- patients who had used analgesics 6 hours before arriving.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Buprenorphine
Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
|
2 mg sublingual tablet
|
|
Active Comparator: Morphine
Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
|
0.1 mg/kg IV morphine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in pain score
Time Frame: 20 and 40 minutes
|
change in pain severity based on Numerical Rating Score
|
20 and 40 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
treatment side effects
Time Frame: 40 minutes
|
experiencing any side effects by the patients as a result of treatment protocols.
|
40 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mohammad Jalili, MD, TUMS
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 130-1848
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.